Optimi Health Secures CAD$1 Million in Non-Dilutive Debt Financing

TORONTO— Optimi Health Corp., a Canadian pioneer in psychedelic substance research and production, has successfully secured a non-dilutive Debt Financing Agreement (DFA) for a sum of CAD$1,000,000. This loan, provided by an arm’s length party, represents a strategic move by the company to advance its research and development initiatives without diluting shareholder value.

Licensed by Health Canada for the production of compounds such as MDMA and high-grade natural psilocybin, Optimi Health is at the forefront of the burgeoning field of psychedelic research. The financing, complemented by a General Security Agreement (GSA), underlines the lender’s confidence in Optimi’s potential and the growing market interest in psychedelic-based treatments.

Under the terms of the DFA and GSA, the loan is secured by the company’s assets and carries an interest rate of 7.5% per annum. Payments are structured on a quarterly basis, with the full repayment of the principal due on April 30, 2025. However, the company retains the right to repay the loan earlier if desired, subject to a prepayment fee, allowing for financial flexibility.

In conjunction with the loan, Optimi Health has issued 100,000 common share purchase warrants to the lender. These warrants provide the lender with the option to purchase additional common shares in the company at a price of $0.50 for a period of three years following the issuance date.

This financial maneuver is indicative of the company’s commitment to maintaining a robust balance sheet while expanding its operations. The loan is a testament to Optimi Health’s credibility and the viability of its research in the field of psychopharmacology, an area that has seen increasing interest due to its potential therapeutic applications.

As the scientific community continues to explore the benefits of psychedelic substances for mental health treatments, companies like Optimi Health are gaining traction. With a secure financial runway and a focus on Good Manufacturing Practices (GMP) quality standards, Optimi is poised to play a significant role in the development of evidence-based psychedelic therapies.